anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a method for preparing milk tablets with micron ash tree frondosa powder glossy ganoderma spore powder for anti-tumor mutation. Various kinds of traditional milk tablets are added with micron ash tree bee pollen, micron pine pollen, micron bee pollen, micron ganoderma powder, micron ganoderma spore powder and oligose powder which are crushed into ultrafine powder by high-tech air stream, all kinds of raw material are combined and processed, and a milk tablet for anti-tumor mutation is obtained. The milk tablet has the obvious function of anti-tumour mutation, and simultaneously, the milk tablet has the efficiency for eliminating toxicant, servicing beauty, strengthening immunity, etc. Middle-age people and old people can obtain hundreds of kinds of nutrient substances, such as rich vitamins, minerals, active ferments, etc. Simultaneously, because the micron pine pollen, the micron ash tree bee pollen, etc. which are called as a jewelry for facial beautification, servicing beauty, preventing cancer and resisting cancer in the east are added, the milk tablet is good for digestive absorption by a human body, and the health care efficiency for eliminating toxicant, servicing beauty, strengthening immunity, etc. is intensified. Therefore, the milk tablet prepared by the present invention is a good anti-tumour mutation milk tablet product which is especially designed for middle-age people and old people all over the world and especially tumor patients after operations, has the Chinese characteristics and prevents recurrence.
There is lack of very-long term outcomes after bariatric surgery; A few series have been reported. However, most of them analyze medium-term outcomes. For RYGB, there are just two retrospective cohort studies reporting very long-term outcomes. Both studies have an open approach and a proximal Roux-en-Y configuration with different pouch orientation and size. MacLean´s series, with a better follow-up rate (83.4%), had a 67.6%EWL at a mean of 11.4 years; Failure rates were 20 and 35% for the morbidly obese and super obese, respectively. We will analyze our own series with a laparoscopic approach, vertically, lesser-curve base \< 10-15ml pouch and proximal Roux limb. The main end-points for our study are 1) Morbidity including status of specific biochemical markers \& Mortality, 2) Weight loss expressed as BMI or %EWL, 3) Trends in major comorbidities and 4) Assessment of Quality of Life.
Ondansetron 8 mg bolus by vein from 30 minutes before receiving chemotherapy followed by 24 mg by vein continuous infusion daily while receiving chemotherapy until 12 hours after chemotherapy. Aprepitant 125 mg capsule by mouth every morning while receiving chemotherapy followed by 80 mg capsule by mouth daily while receiving chemotherapy continued till 1 day after last chemotherapy dose.
A traditional Chinese medicine composition for improving the poultry feed intake is disclosed. The composition comprises following components by weight: 20-30 parts of hawthorn, 10-20 parts of dark plum, 5-10 parts of rice sprout, 10-15 parts of malt, 5-10 parts of the bark of ash, 5-10 parts of flavescent sophora root, 5-10 parts of radix berberidis, 15-25 parts of bile salt and 3-5 parts of garlic. The composition used for treating poultry feed intake decrease is used for poultry, and has effects of rectifying qi, appetizing, detoxifying, stopping dysentery, tonifying the stomach and helping digestion. When the composition is used for feed intake decrease and significant laying rate decrease which are caused by diseases for laying hens, the significant efficiency is 98.8%, and the effective rate is 99.9%. When the composition is used for feed intake decrease caused by diseases, varieties, environment, and other reasons for table poultry, the significant efficiency is 97.3%, and the effective rate is 99.5%. A production process of the composition is nontoxic, harmless and free of drug residue, and adopts conventional equipment. The composition is simple in process and low in cost, and is convenient for industrialization.
SAD cohorts 1-4. Subjects in each cohort will be randomized to receive a single oral dose of ATH-063 (capsule) under fasting conditions at the planned dose levels.
The association between plasma low-density lipoprotein cholesterol (LDL-C) and atrial fibrillation (AF) recurrence after catheter ablation remains unclear. We aimed to assess the relationship between preprocedural LDL-C and the AF recurrence in patients undergoing catheter ablation. The cohort study consecutively included AF patients who underwent de novo catheter ablation between April 2021 and January 2023 in the Second Affiliated Hospital of Nanchang University in Jiangxi Province, China. Patients were divided into quartiles based on their baseline fasting LDL-C level (Q1-Q4). Multivariable Cox proportional hazards models were used to evaluate the relationship between LDL-C and AF recurrence. Our analysis included the use of a generalized additive model and smooth curve fitting (penalized spline method), and two-piecewise Cox proportional hazards models, to address the nonlinearity between preprocedural LDL-C and AF recurrence. A total of 482 AF patients with de novo catheter ablation were enrolled, with a median follow-up period of 15.00 months, AF recurrence occurred in 96 (19.92%) patients. The relationship between preprocedural LDL-C and AF recurrence after ablation presented as an L-shape, and the inflection point for the curve was found at the LDL-C level of 3.20 mmol/L (Log likelihood ratio P = 0.031). The hazard ratios (HR) [(95% confidence intervals (CI)] for AF recurrence were 0.50 (0.33-0.74) and 2.11 (0.76-5.89) to the left and right of the inflection point, respectively. Lower LDL-C level is associated with increased AF recurrence risk after catheter ablation were consistent across all subgroups.
Patients receive fat emulsion IV immediately before each dose of either carboplatin or oxaliplatin. Treatment continues for up to 2 years in the absence of disease progression or unacceptable toxicity.
Exendin (9-39) is a synthetic peptide that acts as an antagonist to the GLP-1 receptor. Exendin (9-39) will be diluted in saline 0.9% and administered through IV infusion once for a maximum of 2.5 hours in length at 600-750 pM/kg/min.
Systemic lupus erythematosus (SLE) is an autoimmune disease with a variable course with unpredictable flares. Identifying predictors of these flares is essential for monitoring and timely hospital care. To characterize the prevalence of flares within the first five years of SLE diagnosis and determine the clinical and immunological characteristics associated with flare development among patients attending the Rheumatology Clinic at Tikur Anbesa Specialized Hospital (TASH) and Lancet General Hospital. A multicenter, cross-sectional study was conducted from May 2023 to November 2023 at TASH and Lancet General Hospital. The data was collected from electronic medical records and analyzed using SPSS version 26. Logistic regressions were used to determine factors associated with lupus flare. Most patients with SLE were female (95.4%). The most common clinical presentations were musculoskeletal (71.8%), cutaneous (55%), and constitutional (22%). Almost half (44.3%) of the patients had comorbidity illness. Positive ANA test was found in 96.5% of the patients, whereas only 55% had positive anti-dsDNA test. The prevalence of SLE flare in the first five years of SLE diagnosis was 38.9%, and most flares occurred within the first year of diagnosis. Patients with the following characteristics were more likely to have flare-ups: younger age at diagnosis (less than 25 years old), initial presentation with vasculitis, renal flare, and being on low-dose prednisolone. The most common clinical presentations were musculoskeletal, dermatologic, and constitutional manifestations. Age < 25 years at diagnosis, initial clinical presentation with renal manifestation, and being on low-dose prednisolone were predictors of SLE flare. Key Points • This study found a significant gender disparity, with 95% female. • Nearly 39% of patients experienced an SLE flare within the first five years of diagnosis. • Over three-quarters (77%) of flares occurred within the first year of diagnosis. • Age less than 25 years, initial presentation with vasculitis, renal involvement, and being on low-dose prednisolone were identified as predictors of flares.
As a lymphocyte-specific surface receptor belonging to the cysteine-rich superfamily of scavenger receptors, CD6 acts as a pattern recognition receptor for microbial components and is involved in the regulation of inflammatory responses. However, the characteristics and functions of CD6 molecules in lower vertebrates represented by teleost fish are unknown. In this study, a CD6 homolog (designated OnCD6) was characterized from Nile tilapia (Oreochromis niloticus), and establishing its role as a PRRs that participates in immune recognition. OnCD6 contains an open reading frame of 1872 bp that encodes a peptide of 623 amino acids, and contains two conserved SR domain. Multiple sequence alignment revealed that OnCD6 shares a relatively high level of identity with those of other species. Transcriptional expression analysis revealed that OnCD6 was constitutively expressed in immunes tissues such as head kidney and thymus. The expression level of OnCD6 in mainly immune tissues were found significantly upregulated after the injection of Streptococcus agalactiae (S. agalactiae). Moreover, OnCD6 protein was located in the head kidney and brain, mainly over the plasma membrane of lymphocytes in these immune tissues. In vitro experiments showed that CD6 extracellular protein bound to and aggregated several Gram-positive and -negative bacterial strains through the recognition of bacterial surface conserved components LPS and LTA etc. In vivo experiments demonstrated that overexpression OnCD6 before S. agalactiae challenge significantly improved tilapia survival, and this was concomitant with reduced bacterial load and pro-inflammatory cytokines (IL-1β and TNF-α). Taken together, our results illustrated the function of CD6 molecular pattern recognition receptors (PRRs) is conserved and plays an important role in antibacterial infection.
Glucose homeostasis is achieved via complex interactions between the endocrine pancreas and other peripheral tissues and glucoregulatory neurocircuits in the brain that remain incompletely defined. Within the brain, neurons in the hypothalamus appear to play a particularly important role. Consistent with this notion, we report evidence that (pro)renin receptor (PRR) signaling within a subset of tyrosine hydroxylase (TH) neurons located in the hypothalamic paraventricular nucleus (PVNTH neurons) is a physiological determinant of the defended blood glucose level. Specifically, we demonstrate that PRR deletion from PVNTH neurons restores normal glucose homeostasis in mice with diet-induced obesity (DIO). Conversely, chemogenetic inhibition of PVNTH neurons mimics the deleterious effect of DIO on glucose. Combined with our finding that PRR activation inhibits PVNTH neurons, these findings suggest that, in mice, (a) PVNTH neurons play a physiological role in glucose homeostasis, (b) PRR activation impairs glucose homeostasis by inhibiting these neurons, and (c) this mechanism plays a causal role in obesity-associated metabolic impairment.
Patient was in supine position, placing the soles of his feet against the wall so that the ankle, knee, and thigh joints are at a 90-degree angle. The subject placed a 3-4-inch ball between his/her knees, which he/she has to maintain through the pressure of the internal thigh muscles during the whole training period and puts his/her back on the bed. Holds the right hand above the head and the left hand with the balloon. Meanwhile examiner palpated 1st rib with head in left side flexion. Patient was then asked to inhale through the nose in three-four seconds and then exhales slowly into the balloon. Then, holding the first rib in place, the patient was asked to inhale and exhale deeply again. The examiner continued applying pressure to hold the first rib in a position of relative depression during inhalation, and further depress the first rib as able during exhalation.
This is the active comparator as a fixed-dose combination of artemether and lumefantrine which is produced by Novartis (Switzerland). The drug will be used as the comparator because it is the only fixed-dose combination with artemether currently available. Administered in children as tablets containing Artemether-Lumefantrine at (20mg/120mg) for body weights of 5-10kg every 12H within 48H.
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) represents a group of small vessel vasculitides characterized by granulomatous and neutrophilic tissue inflammation, often associated with the production of antibodies that target neutrophil antigens. The predominantly used treatment for induction of remission in AAV consisted of cyclophosphamide (CYC) plus corticosteroids (GCs) which leads to remission in about 90% of patients. However, relapses are frequent and remain a challenge. The optimal drug for maintenance treatment is not determined. Tofacitinib is a Jak inhibitor which has been proved to be effective in multiple inflammatory diseases such as rheumatoid arthritis. Considering that T cells and associated cytokine production play an important role in the pathogenesis of AAV via activation of the JAK/ STAT pathway, we hypothesized that tofacitinib-mediated inhibition of JAK signaling may represent an effective therapy for active AAV. In this prospective, open label, single arm study, tofacitinib 5mg twice a day will be added to the background treatment of GCs and immunosuppressants in AAV, the safety and efficacy of tofacitinib will be assessed.
Insulin resistance is a central feature of type II diabetes and other diseases, and may affect every tissue of the body, including the pancreatic beta cell. Insulin signaling is mediated by a complex network of diverging and converging pathways, with alternative proteins and isoforms at almost every step in the process. We have previously shown that insulin activates the transcription of its own gene by signaling through Insulin Receptor A type (Ex11−), PI3 kinase and p70 s6 kinase. When studying the mechanisms underlying the glucose-stimulated activation of the glucokinase gene in pancreatic beta cells, we now demonstrate that also here secreted insulin is a key-factor. In contrast to the insulin gene, transcription of the glucokinase gene is promoted by signaling via Insulin Receptor B type (Ex11+) and protein kinase B (c-Akt). These data provide the first evidence for selectivity in insulin action via the two isoforms of the Insulin Receptor, A type (Ex11−) and B type (Ex11+), and reinforce the concept of the beta cell being an important target of insulin action.
The intervention technique used is ''The electric vibrating massager'', ''SAMPO®'', and patients are taught to apply the strong mode on the 15 specific points,5 min each, 3 times a day from Monday to Friday during chemotherapy course. The intervention follows the points are used to stimulate the hematopoietic function. including Hegu (LI4), Quchi (LI11), Xuehai (SP10); Sanyin-jiao (SP6), Taixi (K3), Zusanli (ST36), Taichong (LV3), Baihui (GV20). Before the study, the trained study nurses teach patients that how to use the technique and stuck adhesive dots label on each specific acupoints.
Dual anti-aggregant therapy is recommended standard of therapy applicable to all patient groups undergoing PPCI. The aspirin-clopidogrel regiment is signed to every patient without assessing therapeutic effect. In face of growing evidence of platelet resistance to the standardized therapy there is a demand for reliable diagnostic tool for rapid and accurate assessment of platelet reactivity. TEG is an established technique to assess the quality of clot formation' used mainly in surgery and obstetrics to determine possible bleeding diathesis. Recently it became to be used in cardiology, where it can be a valuable tool to assess a response to antiplatelet therapy and its association with the outcome. However, there is a few data about use of TEG in STEMI patients undergoing PCI. Our study is designed to assess by TEG the platelet's response to clopidogrel treatment during acute STEMI in patients undergoing primary PCI and the correlation of this response with the long term outcome.
PURPOSE:To obtain a new thiazolidine compound useful as an antidiabetic agent and an antihyperlipidemic agent, having relieving activity, etc., for insulin resistance in peripheral tissues, etc., and composed of a specific thiazolidine compound containing benzoquinonyl group, etc. CONSTITUTION:1,4-dimethoxy-2,3,5-trimethylbenzene is oxidized in a solvent to a phenol derivative, which is subjected to reaction with p-fluoronitrobenzene and then reduced to give 4-(2,5-dimethoxy-3,4,6-trimethylphenoxy)aniline. This compound is then treated with sodium nitrite and subjected to reaction in sequence with butyl acrylate and cupric bromide to lead to a compound of formula I (R<1> is C1-5 alkyl; R<2> and R<3> are C1-5 alkyl, alkoxy, etc.; W is a single bond or C1-5 alkyl; Y<1> is methyl or acetyl; X is halogen; A is carboxy, ester, etc.), which is subjected to reaction with thiourea and then eliminated a protecting hydroxy group and oxidized to give the objective compound of formula II (R<4> and R<5> are H or make a single bond together between them; Z is H, alkali metal, etc.).
Methods are provided for preventing or treating risk factors for cardiovascular disease in an individual, comprising administering a therapeutically effective amount of a composition comprising an estradiol metabolite to said individual. Such risk factors include obesity, the metabolic syndrome, diabetes mellitus, vascular disorders, and renal disorders. Preferred estradiol metabolites include 2-methoxyestradiol, 4- methoxyestradiol, 2-hydroxyestradiol, and 4-hydroxyestradiol or prodrugs thereof. The compositions may also be in the form of a controlled release formulation. Methods are also provided for use of estradiol metabolites to treat or prevent insulin resistance, vascular endothelial dysfunction, hyperlipidemia, hypertension, diabetic nephropathy, proteinuria and reducing leptin levels. In addition, the methods provide a method of stabilizing glucose levels. These treatments may be used in either gender because of their lack of a feminizing estrogenic effect.
PURPOSE:To provide spherical active carbon having excellent detoxificating effect but not having adverse after effect by a method wherein specified spherical active carbon prepared from raw material pitch or the like is sieved and then treated with ammonia. CONSTITUTION:Pitch is melted and formed into small spheres, is cooled, heated and carbonized in inert gas, activated by heating in steam, and sieved to provide small spherical active carbon having the following properties: Diameter: 0.05-2mm., surface area: 500-2,000m<3>/g; pore volume of pores having 100-75,000Angstrom  pore dia. 0.05-1ml/g; true sphere: more than 85% of the total amount, and the ratio of maximum to minimum diameter: 1-3. Then a mixture of said sphericial active carbon with an aq. ammonia contg. 1-1,000 ppm NH3 is prepd. wherein the volume ratio of the aq. soln. to active carbon is 2-10, then the mixture is treated at 10-50 deg.C for 0.5-5hr, and dried at 100-150 deg.C. The pH is adjusted to 6-8.
Persistent human papillomavirus (HPV) infection is associated with multiple malignancies. Developing therapeutic vaccines to eliminate HPV-infected and malignant cells holds significant value. In this study, we introduced a lipid nanoparticle encapsulated mRNA vaccine expressing tHA-mE7-mE6. Mutations were introduced into E6 and E7 of HPV to eliminate their tumourigenicity. A truncated influenza haemagglutinin protein (tHA), which binds to the CD209 receptor on the surface of dendritic cells (DCs), was fused with mE7-mE6 in order to allow efficient uptake of antigen by antigen presenting cells. The tHA-mE7-mE6 (mRNA) showed higher therapeutic efficacy than mE7-mE6 (mRNA) in an E6 and E7+ tumour model. The treatment resulted in complete tumour regression and prevented tumour formation. Strong CD8+ T-cell immune response was induced, contributing to preventing and curing of E6 and E7+ tumour. Antigen-specific CD8+ T were found in spleens, peripheral blood and in tumours. In addition, the tumour infiltration of DC and NK cells were increased post therapy. In conclusion, this study described a therapeutic mRNA vaccine inducing strong anti-tumour immunity in peripheral and in tumour microenvironment, holding promising potential to treat HPV-induced cancer and to prevent cancer recurrence.
Provided is a pharmaceutical composition containing natural plants, which have antiphlogistic, pain, antifebrile, oxygen-resistant and anti-histamine effects for treatment of atopic asthma and allergic rhinitis. A pharmaceutical composition containing natural plants comprises the 4-40 parts of Platycodon grandiflorum A. De Candolle, the 2-20 parts of Glycyrrhiza uralensis, the 1-10 parts of Mentha arvensis var. piperascens, the 0.5-10 parts of propolis and the 1-10 parts of menthol by weight. The pharmaceutical composition is formulated as troche. A method for preparing the pharmaceutical composition consists of the following steps of: mixing the Platycodon grandiflorum A. De Candolle and Glycyrrhiza uralensis and reflux-extracting the mixture with water or ethanol to obtain mixed herbs extracts; and mixing propolis and menthol to the mixed herbs extracts.
As medical technology continues to evolve, it becomes crucial to distinguish the outcomes of traditional versus modern surgical techniques. This was a retrospective cohort study, conducted to compare the wound infection rates and recovery outcomes between laparoscopic and open surgery (OS) in 180 patients. Participants were divided into laparoscopic (n = 105) and OS (n = 75) groups. Comprehensive data, including demographics, surgical details, and postoperative outcomes, were extracted. Wound infection rates, as measured by Wound Asepsis Score, were prioritized alongside recovery indicators such as duration of hospital stay and postoperative pain. The laparoscopic group had a mean operative time of 57.19 minutes, while the OS group required 85.10 ± 15.18 minutes (p < 0.05). Laparoscopic surgeries resulted in an average blood loss of 120.76 ± 13.3 mL compared to 170.01 ± 17.19 mL for OS (p < 0.05). The laparoscopic group had significantly reduced (p < 0.05) average hospital stays (2.1 ± 1.1 days) than the OS group (4.4 ± 2.1 days). Although the laparoscopic group had lower incidence of surgical site infection (4.76%) than the OS group (9.33%), this difference was not statistically significant (p > 0.05). On postoperative days 1, 3, and 7, the Visual Analog Scale assessment of pain in the laparoscopic group revealed significantly reduced pain (p < 0.05). Laparoscopic surgery appeared to offer distinct advantages over conventional open surgery, especially in terms of operative durations, recovery rates, and postoperative pain management. This study highlighted the potential of laparoscopic approaches for specific surgical interventions, as well as the importance of patient-specific surgical strategy decision-making.